瑞莱,ReLIA Diagnostics,  
瑞莱生物工程（深圳）有限公司是美国加州著名的 ReLIA 生物科技公司在中国的独资企业，于2001年在深圳市高新技术产业园区注册成立，注册资金440万美元，投资总额800多万美元。

公司主要从事高新生物技术产品的研发及产业化生产,其自主开发的ReLIA检验系统与21世纪世界医学检验学的重要发展趋势同步，具备“快速、简便、全血、定量检测”等床边即时检验技术（POCT）的各种优点，是国内率先拥有多项国际自主知识产权的POCT技术体系。企业已获得国家食品药品监督管理局(SFDA)颁发的《药品生产许可证》和《医疗器械生产许可证》等证书，相关诊断试剂产品和检验仪器均拥有产品注册证书。

公司拥有国际一流的研发和生产基地,其10万级GMP标准洁净厂房已获得国家药监局(SFDA)的GMP认证,生产和质量管理体系完全按照药品GMP、ISO13485以及欧盟CE-MARK标准执行。

Rutter 博士现为 ReLIA（瑞莱）生物科技公司的董事长、美国高科技控股公司 Synergenics 的董事长兼首席执行官，美国科学院院士、加州大学医学院 (UCSF) 荣誉教授。 Rutter 博士曾创办美国著名的生物制药企业 Chiron 公司，并任该公司董事长多年，同时还兼任国际大型制药企业如诺华 Novartis 公司、默克 Merck 公司的董事会成员。

Rutter 博士在国际生物技术和重组基因工程领域做出过许多重大的贡献。他领导的实验室首次克隆了人类胰岛素基因、首次利用 DNA 重组技术研制出乙型肝炎疫苗，1987 年更是首先发现并克隆了丙型肝炎病毒HCV，为发展高灵敏度病毒检测试剂、疫苗以及治疗药物奠定了良好的基础，先后发表了 380 多篇学术论文。他曾任美国加州大学医学院生物化学系主任多年，任内该系诞生过两位诺贝尔医学奖获得者。

Our goal is to provide central lab quality diagnostic testing to medical caregivers wherever fast, on-the-spot blood tests can improve the quality of patient care. When multiple biomarkers together can provide better information than a single biomarker can, we provide low-cost multiplexed tests with instant decision-making information. Bringing timely, high quality diagnostic information to the point-of-care will enhance the patient-doctor discussion and personalize follow-up treatment. Our strategy is to offer cardiovascular, cerebrovascular, acute kidney injury, and infectious disease biomarker panels in customer-proximity and point-of-care locations throughout the world.

Founder

William J. Rutter, Founder

Dr. Bill Rutter is Chairman and founder of ReLIA. The company is located in San Francisco’s Mission Bay /UCSF biomedical complex. It is a privately held company, under the umbrella of Synergenics LLC.

Dr. Rutter is also Chairman and CEO of Synergenics, which provides an innovative approach to advancing medical innovation into profitable start-up companies in the life sciences industry. Synergenics provides member companies (e.g., Humabs, Ventria, Synco, Numera, Pathologica, BioE, Epitomics) with investment, shared laboratories, scientific and industry expertise, and experienced management and administrative services. Synergenics provides a collaborative environment for the exchange of ideas and technology, while protecting each company’s IP.

Dr. Rutter is a member of the National Academy of Sciences and American Academy of Arts and Sciences and he has received numerous awards for his contributions to science and the biotechnology industry. He is Herzstein Professor Emeritus of Biochemistry at the University of California, San Francisco (UCSF). He co-founded Chiron Corporation (NASD: CHIR, acquired in 2005 by Novartis) and served as its Executive Chairman. Since the acquisition, Novartis has continued to build upon Chiron’s leadership in molecular diagnostic and vaccines. He has served on the boards of Novartis and numerous public and private biotechnology companies.